NASDAQ
Genprex, Inc. (GNPX)
♥ 559 Thanks from members
Genprex, Inc. (GNPX) faces intense scrutiny amid a going concern warning, a 1-for-22 reverse stock split, and a conditional Nasdaq listing extension requiring a $1.00 minimum bid price through December 2026, offset by recent diabetes gene therapy CDMO scale-up milestones and an equity-boosted cash runway into 2027.